What is HC Wainwright’s Forecast for COLL Q4 Earnings?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Analysts at HC Wainwright issued their Q4 2026 earnings estimates for shares of Collegium Pharmaceutical in a report issued on Friday, January 9th. HC Wainwright analyst B. Folkes expects that the specialty pharmaceutical company will post earnings per share of $1.66 for the quarter. HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Collegium Pharmaceutical’s current full-year earnings is $5.62 per share.

Several other equities research analysts have also weighed in on COLL. Barclays reduced their price objective on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a research note on Friday, January 9th. Needham & Company LLC upped their target price on Collegium Pharmaceutical from $48.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Truist Financial set a $55.00 price target on Collegium Pharmaceutical in a research note on Wednesday, January 7th. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $52.80.

Collegium Pharmaceutical Trading Down 1.8%

Collegium Pharmaceutical stock opened at $47.28 on Monday. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of 29.37 and a beta of 0.60. Collegium Pharmaceutical has a 1 year low of $23.23 and a 1 year high of $50.79. The firm’s 50 day moving average price is $46.70 and its two-hundred day moving average price is $38.86. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.27 and a current ratio of 1.36.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, November 6th. The specialty pharmaceutical company reported $2.25 EPS for the quarter, topping analysts’ consensus estimates of $1.89 by $0.36. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. The business had revenue of $209.36 million for the quarter, compared to the consensus estimate of $191.25 million. During the same period in the previous year, the firm earned $1.61 EPS. The business’s revenue for the quarter was down 18.9% on a year-over-year basis.

Insider Transactions at Collegium Pharmaceutical

In related news, CFO Colleen Tupper sold 30,000 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the completion of the sale, the chief financial officer directly owned 126,667 shares in the company, valued at approximately $5,133,813.51. This trade represents a 19.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Scott Dreyer sold 17,600 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $48.17, for a total value of $847,792.00. Following the completion of the transaction, the executive vice president owned 103,613 shares in the company, valued at $4,991,038.21. This trade represents a 14.52% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 51,250 shares of company stock valued at $2,235,352. 2.51% of the stock is owned by insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of hedge funds have recently added to or reduced their stakes in COLL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Collegium Pharmaceutical by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock worth $569,000 after purchasing an additional 825 shares in the last quarter. Millennium Management LLC lifted its position in shares of Collegium Pharmaceutical by 248.5% in the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after buying an additional 461,914 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Collegium Pharmaceutical by 7.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock worth $2,120,000 after acquiring an additional 4,625 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of Collegium Pharmaceutical by 218.7% during the 1st quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock valued at $3,926,000 after acquiring an additional 90,255 shares during the last quarter. Finally, Intech Investment Management LLC increased its holdings in shares of Collegium Pharmaceutical by 10.1% during the 1st quarter. Intech Investment Management LLC now owns 73,908 shares of the specialty pharmaceutical company’s stock valued at $2,206,000 after acquiring an additional 6,776 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.